Amylyx Pharmaceuticals (AMLX) Enterprise Value (2021 - 2026)

Amylyx Pharmaceuticals' Enterprise Value history runs 6 years deep, the most recent figure standing at -$279.8 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 37.1% year-over-year to -$279.8 million; the TTM figure through Mar 2026 stood at -$279.8 million (down 37.1% YoY), while the FY2025 annual figure was -$317.0 million, down 79.59% from the prior year.
• Enterprise Value was -$279.8 million for Q1 2026 at Amylyx Pharmaceuticals, up from -$317.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$162.6 million in Q3 2022 to a low of -$373.3 million in Q1 2024.
• Historically, Enterprise Value has averaged -$283.6 million across 5 years, with a median of -$309.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value tumbled 260.96% in 2022, then surged 52.47% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$346.9 million in 2022, then slipped by 7.04% to -$371.4 million in 2023, then soared by 52.47% to -$176.5 million in 2024, then sank by 79.59% to -$317.0 million in 2025, then rose by 11.74% to -$279.8 million in 2026.
• The last three Enterprise Value figures came in at -$279.8 million (Q1 2026), -$317.0 million (Q4 2025), and -$344.0 million (Q3 2025), per Business Quant data.